Organogenesis Holdings stock (US68620V1026): Q1 earnings miss on revenue and EPS
Published on 05/12/2026 at 14:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Organogenesis Holdings released its Q1 2026 earnings on May 7, 2026, reporting an EPS of -$0.37, which missed the consensus estimate of -$0.29 by $0.08, MarketBeat as of May 2026. Quarterly revenue came in at $37.23 million, below analysts' expectations of $43.26 million. The stock traded at $2.33 on May 11, 2026 on Nasdaq, down 1.69% from the prior close, StockInvest.us as of 05/11/2026.
As of: 12.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Organogenesis Holdings Inc.
- Sector/industry: Drug Manufacturers - Specialty & Generic
- Headquarters/country: United States
- Core markets: North America
- Home exchange/listing venue: Nasdaq (ORGO)
- Trading currency: USD
Official source
For first-hand information on Organogenesis Holdings, visit the company’s official website.
Go to the official websiteOrganogenesis Holdings: core business model
Organogenesis Holdings develops and markets solutions for the advanced wound care and surgical biologics markets. The company focuses on regenerative medicine products, including tissue-engineered skin substitutes and wound care therapies primarily used in the treatment of chronic and acute wounds. These products are sold to healthcare providers in the United States, with a presence in North American markets. The business model relies on innovation in biologics to address unmet needs in wound healing and tissue repair.
Main revenue and product drivers for Organogenesis Holdings
Key products include Apligraf and PuraPly, which are human skin substitutes and wound care dressings generating the majority of revenue. In Q1 2026, reported revenue of $37.23 million reflected demand in advanced wound care, though it fell short of expectations published as of May 7, 2026, MarketBeat as of May 2026. Trailing twelve-month EPS stood at -$0.19 as of the latest report. The company maintains a market cap of approximately $304.96 million, with shares at $2.37 noted in recent data, WallStreetZen as of 2026.
Industry trends and competitive position
The advanced wound care segment benefits from rising demand due to aging populations and increasing prevalence of chronic wounds like diabetic foot ulcers in the US. Organogenesis competes with players in regenerative biologics, holding a position in specialty generics with EBITDA of $35.99 million reported for the period ending in recent filings, per WallStreetZen as of 2026. US investors track this space for exposure to healthcare innovation amid sector growth.
Why Organogenesis Holdings matters for US investors
Listed on Nasdaq, Organogenesis provides US investors direct access to regenerative medicine advancements addressing domestic healthcare needs, such as wound care for an aging population. Its products support hospitals and clinics nationwide, tying into broader US medical spending trends.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Conclusion
Organogenesis Holdings' Q1 2026 results showed revenue and EPS misses amid ongoing operations in advanced wound care. The stock has experienced volatility, trading at $2.33 on May 11, 2026 on Nasdaq. Investors monitor regenerative medicine developments for potential in the US healthcare market. Market dynamics and future quarters will shape the trajectory.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
